Zavain Dar - Apr 3, 2023 Form 4/A - Amendment Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Apr 3, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
4/28/2023, 04:34 PM
Date Of Original Report
Apr 5, 2023
Previous filing
Jul 12, 2022
Next filing
Jun 21, 2023
SEC
View on sec.gov

Transactions Table

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 Includes a total of 35,008 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the original Form 4 filing.